Preparation method of Pengfibrate tablet
Through the process of combining wet granulation and direct powder tableting, Pemabet tablets were prepared, which solved the problem of increasing impurities and stability caused by the interaction of active ingredients and cellulose auxiliary materials, and achieved the high efficiency of Pemabet tablets. , safe and economical production ensures the physical and chemical stability and efficacy of the product.
Patent Information
- Application Number
- CN202411261127.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-11-08
AI Technical Summary
The preparation process of the existing Pemabet tablets has the risk of mixing uniformity and safety effectiveness when interacting with cellulose excipients under high humidity conditions, resulting in increased impurities and poor storage stability, and low doses lead to risks of mixing uniformity and safety effectiveness. The process lacks reproducibility, and the wet granulation process or direct powder tableting process commonly used has problems such as difficult and high cost in preparation.
The wet granulation process is used to prepare particles containing high proportion of pemabel and then crush them, mix them with non-cellulose auxiliary materials, and add lubricant, disintegrant and binder to prepare tablets through direct powder tableting process to avoid The active ingredients are in direct contact with cellulose auxiliary materials, control moisture and particle size, and optimize the auxiliary material ratio and process steps to improve content uniformity and chemical stability.
The content uniformity and initial impurity level of Pemabet tablets are achieved, which improves chemical stability and safety, avoids the impact of process variables on product quality, reduces production costs, and ensures long-term storage Efficacy and safety.
Smart Images

Figure CN118903030A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical preparations, and specifically relates to a method for preparing Pemabet tablets. Background Art
[0002] Pemabet is a selective peroxisome proliferator-activated receptor α (PPARα) modulator that can improve lipid metabolism. It was developed by Japan Kowa Co., Ltd. It has the effects of lowering plasma triglycerides, increasing high-density lipoprotein cholesterol, and resisting arteriosclerosis, and is used to treat hyperlipidemia. Its products sold in Japan are oral immediate-release tablets and sustained-release tablets, but these two dosage forms have not yet been marketed in China.
[0003] Since the specifications of Pemabet tablets are relatively small (the oral rapid-release tablets currently on the market in Japan contain 0.1 mg of Pemabet per tablet), they are low-dose drugs. Due to their extremely low unit drug content, they are very susceptible to loss and contamination during the production process; therefore, their preparation process requires extremely sensitive analytical methods and extremely sophisticated pretreatment methods, and a good recovery rate is obtained; in addition, the content uniformity of the final product and the stability of the product during production and storage are both required to be high. For low-dose drug preparations, their prescription research, process development and scale-up production, quality control and establishment of analytical methods are more difficult than those for conventional preparations. Compared with liquid preparations, low-dose solid drug preparations are more challenging.
[0004] The commonly used preparation process for Pemabet tablets is to adopt a wet granulation process or a powder direct tableting process to directly mix Pemabet with cellulose excipients. However, when Pemabet coexists with celluloses represented by hydroxypropyl cellulose, they interact with each other under high humidity conditions, resulting in an increase in impurities and poor storage stability.
[0005] It was also discovered in early development that the extremely low specifications of Pemabet tablets made it difficult to mix the active ingredients evenly with the excipients. Even if the cumbersome step-by-step mixing method was used, when the API was stored for a long time and the aggregation state changed, the established mixing process could not always meet the expected mixing requirements. Additional process steps might be required for control, such as adding an API crushing process, extending the mixing time, adjusting the order of adding excipients / the amount added in each step during mixing, etc., that is, the production process lacked reproducibility. In addition, the specification of Pemabet tablets is 0.1 mg. Although reducing the tablet weight can also help improve the mixing uniformity, the fluctuation of tablet weight will have a greater impact on the content uniformity, creating safety and effectiveness risks.
[0006] Chinese patent CN110809470A discloses a method for stabilizing pemafibrate or its salt or their solvate in a pharmaceutical composition, that is, by placing a pharmaceutical composition containing pemafibrate or its salt or their solvate and cellulose in an airtight package that can inhibit the substantial intrusion of moisture, the increase of the decomposition product of pemafibrate can be inhibited, and excellent storage stability can be obtained. Although the use of an outer package with good airtightness can protect the chemical stability, after the outer package bag or medicine bottle is opened, the patient takes it in a humid environment (such as rainy season, living near rivers and seas, etc.), and the active ingredient may still be degraded, especially for the case of taking half a tablet, the safety risk is significantly increased.
[0007] Therefore, it is necessary to conduct in-depth research on the production process of Pemabet tablets, and provide a Pemabet tablet that is convenient to produce and operate, saves production costs, has stable physical and chemical properties, and has guaranteed safety and effectiveness. Summary of the invention
[0008] The present invention provides a method for preparing Pemabet tablets, which comprises first preparing granules containing a high proportion of Pemabet, then crushing the granules, mixing with direct compression excipients, and finally compressing the granules, thereby improving the uniformity of the content of active ingredients, reducing the level of impurities in tablets, optimizing the production process, and effectively avoiding the influence of process variables on product quality. The product of the present invention has stable properties, and its effectiveness and safety are more guaranteed.
[0009] The present invention is mainly achieved through the following technical solutions:
[0010] The present invention provides a method for preparing Pemabet tablets, comprising the following steps:
[0011] (2) preparing granules containing Pemabet and non-cellulose excipients, drying, and testing the moisture content of the granules;
[0012] (2) crushing the granules containing Pemabet and mixing them with direct compression tablet excipients;
[0013] (3) adding lubricant and tableting;
[0014] The non-cellulose auxiliary material includes one or a combination of any two or more of sucrose, starch, lactose, lactose hydrate, and mannitol;
[0015] The direct compression tablet excipients include one or a combination of any two or more of lactose, sucrose, microcrystalline cellulose, mannitol, phosphate, lactose-microcrystalline cellulose complex, and lactose-microcrystalline cellulose-starch complex.
[0016] According to an embodiment of the present invention, the direct compression tablet excipient is preferably a lactose-microcrystalline cellulose complex or a lactose-microcrystalline cellulose-corn starch complex.
[0017] According to an embodiment of the present invention, in the composition of Pemabate and non-cellulose auxiliary materials in step (1), the ratio of Pemabate to the auxiliary materials is 1:10 to 1:100, preferably 1:10 to 1:50.
[0018] According to an embodiment of the present invention, the moisture content of the material after drying in step (1) does not exceed 4.0%, preferably does not exceed 2.0%, and more preferably does not exceed 0.5%.
[0019] According to an embodiment of the present invention, the particle size D90 of the particles containing Pemabet after crushing in step (2) does not exceed 100 μm, and preferably does not exceed 50 μm.
[0020] According to an embodiment of the present invention, in step (2), the proportion of Pemabet particles in the mixed material does not exceed 10% (w / w), preferably does not exceed 5% (w / w).
[0021] According to an embodiment of the present invention, a lubricant, a disintegrant, and a binder may be added in the preparation step (2).
[0022] According to an embodiment of the present invention, the lubricant is magnesium stearate or talc.
[0023] According to an embodiment of the present invention, the disintegrant is one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and cross-linked sodium carboxymethyl cellulose.
[0024] According to an embodiment of the present invention, the adhesive is one or more of pregelatinized starch, copovidone, hydroxypropyl methylcellulose, ethyl cellulose, and hydroxypropyl cellulose.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] (1) The present invention provides a process for preparing Pemabet tablets by combining wet granulation with direct compression of powders. This process avoids the degradation of Pemabet due to direct contact with cellulose excipients, improves the uniformity of the content of active ingredients, eliminates the need to separately crush the more active Pemabet, and avoids harm to production operators caused by high concentrations of active ingredients.
[0027] (2) Since the formula contains powdered direct-compression excipients, even if the moisture content of the particles of Pemabet and non-cellulose excipients is controlled at a low level, it will not affect the compressibility and formability of the tablets; and the low moisture content of the particles can further protect the chemical stability of the tablets.
[0028] (3) Tablet forming properties depend on the type and amount of powder direct compression excipients. The process described in the present invention can especially use cellulose excipients that can provide excellent compressibility, thereby avoiding the unfriendly powder properties of the raw material or improper front-end production process parameters affecting tablet forming.
[0029] (4) The Pemabet tablets obtained by the preparation method of the present invention have uniform content, low initial impurity level, and good physical and chemical stability. After long-term storage, they can ensure definite efficacy and safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 This is a diagram of the particle size of the wet granulated material after crushing of Example 5 of the present invention.
[0031] Figure 2 This is the HPLC chromatogram of related substances in the tablet of sample 0 of Example 5 of the present invention.
[0032] Figure 3 This is a high performance liquid chromatogram of related substances in the tablets of Example 5 of the present invention after the sample was kept at 40°C / 75%RH for 3 months. DETAILED DESCRIPTION
[0033] The present invention is further described below in conjunction with specific examples and drawings. It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. After reading the present invention, modifications of various equivalent forms of the present invention by those skilled in the art all fall within the scope defined by the claims attached to this application. Unless otherwise specified, the raw materials used are obtained by self-production.
[0034] Test Example 1 Compatibility Study of Raw Materials and Auxiliary Materials
[0035] This test example is used to verify the effect of the type of excipients on product stability. The raw and excipients are weighed at a ratio of 1:5 (w / w), mixed manually and transferred to a surface dish, dispersed until the powder thickness does not exceed 3mm, and samples are retained according to the conditions in the table below. The growth of impurities in the retained samples under different conditions is investigated, and the results are shown in Table 1.
[0036] Table 1 Impurity growth under different conditions after mixing raw materials and auxiliary materials
[0037]
[0038] From the test data in Table 1, it can be seen that after keeping the samples at high temperature of 60℃ for one month, the compatibility of the raw materials and auxiliary materials is good. After keeping the samples at high humidity of 92.5%RH for one month, the total impurity level of the cellulose auxiliary material group is higher than that of the non-cellulose auxiliary material group. This shows that when Pemabet coexists with cellulose auxiliary materials, they interact with each other under high humidity conditions, and the impurities increase.
[0039] However, the structural characteristics of cellulose excipients make them play a very critical role in product development. Since there are a large number of hydrogen bonds between the molecules of this type of excipient, the hydrogen bonds are associated when compressed, so they have a high degree of compressibility and molding effect. After oral administration, the stomach fluid can quickly enter the tablet containing cellulose excipients, and the hydrogen bonds can be broken, so it can provide a certain disintegration effect and promote drug absorption. In addition, cellulose excipients have good fluidity and have a certain degree of adhesion, so they can be suitable for direct powder tableting process.
[0040] However, the solubility of Pemabet raw materials in water is low, and the development of tablets requires the use of water-soluble excipients such as lactose or mannitol in combination with cellulose excipients to promote rapid dissolution and effectiveness of the drug.
[0041] Therefore, the subsequent process avoids direct contact between Pemabet and cellulose excipients, and the selected cellulose excipients are suitable for the direct powder tableting process. The wet granulation process is combined with the direct powder tableting process. Specifically, non-cellulose excipients are first used to mix with Pemabet, wet granulate, and dry; then the dry granules containing Pemabet are crushed, and cellulose excipients and other excipients suitable for direct powder tableting are added, mixed, and tableted. Under the premise of using cellulose excipients to ensure tablet forming and drug absorption, the coexistence of Pemabet and cellulose excipients is also avoided to ensure the chemical stability of the product.
[0042] The following test examples and examples provide sample quality evaluation indicators, methods, and acceptance criteria:
[0043] Powder mixing content uniformity: 20 minutes after the addition of Pemabet, samples were taken at 4 different positions around the wet granulator and the middle position to test the content. The average value was between 95.0 and 105.0%, and the RSD did not exceed 3.0%.
[0044] Moisture content after drying: Infrared moisture meter, 80℃ heating weight loss method, report the value.
[0045] Particle size after crushing: Malvern particle size analyzer, dry method test, report D 90 Numeric value.
[0046] Tablet hardness: The average value of the hardness of 10 tablets is reported.
[0047] Tablet weight variation: RSD of 10 tablet weights, not exceeding 5.0%.
[0048] Content uniformity: HPLC was used to detect the contents of 10 tablets respectively, and the mean and standard deviation S were calculated. A+2.2S≤15.0%, where A is the absolute value of the difference between the labeled amount and the content mean.
[0049] Content: Grind 5 tablets, weigh appropriate amount of powder to prepare solution, and detect by HPLC. The content is 95.0-105.0% at 0 o'clock and 90.0-110.0% after retaining the sample at 40℃ / 75%RH for 3 months.
[0050] Related substances: Grind 5 tablets, weigh an appropriate amount of powder to prepare a solution, and detect it by HPLC. The total amount of impurities does not exceed 0.5% at 0 o'clock. After retaining the sample at 40℃ / 75%RH for 3 months, the total amount of impurities does not exceed 2.0%.
[0051] Dissolution: pH = 1.2 hydrochloric acid aqueous solution, 900ml, 37±0.5℃, paddle method 50rpm, 30min sampling, take 6 tablets, HPLC detection, the average dissolution of 6 tablets at 0 time is not less than 85%. After retaining the sample at 40℃ / 75%RH for 3 months, the average dissolution of 6 tablets is not less than 75%.
[0052] Test Example 2 Investigation of the ratio of Pemabet to non-cellulose excipients
[0053] In the Pemabet granules, the ratio of active ingredients to non-cellulose excipients affects the mixing uniformity. The samples were prepared according to the following prescription process:
[0054] Table 2 Proportion of Pemabet and non-cellulose excipients
[0055]
[0056] Preparation method:
[0057] (1) Add mannitol and starch to the wet granulator, start stirring and shearing, mix for 5 minutes, add Pemabet, stir and shear and mix for 20 minutes, and clean the powder adhering to the inner wall of the equipment into the mixed material at 5 and 15 minutes respectively;
[0058] (2) Check the uniformity of powder mixing content.
[0059] Powder mixing content uniformity test results:
[0060] Table 3 Effect of the ratio of Pemabet to non-cellulose excipients on the uniformity of powder mixing content
[0061] Prescription 1 Prescription 2 Prescription 3 Prescription 4 Prescription 5 Mean(%) 95.6 96.1 96.9 98.2 99.5 RSD(%) 5.5 3.2 2.3 1.4 0.7
[0062] The above results show that when the proportion of Pemabet is small, the content uniformity is poor after mixing for 20 minutes. When the ratio of Pemabet to non-cellulose excipients is controlled at 1:10-1:100, the RSD can meet the requirements, preferably 1:10-1:50.
[0063] Test Example 3 Effect of moisture content on product quality after drying of Pemabet granules
[0064] Moisture may affect the material fluidity, tablet-related substances, dissolution, and physical and chemical stability during tableting. The samples were prepared according to the following prescription process:
[0065] Table 4 Different Pemabet granule moisture sample prescriptions
[0066] Pemabet Granules Prescription amount (g) Pemabet 4 lactose 240 starch 160 Purified water Moderate Total mixture Prescription amount (g) Pemabet Granules 25 Low substituted hydroxypropyl cellulose 12.5 lactose 110 Microcrystalline Cellulose 100 Magnesium Stearate 2.5
[0067] Preparation process:
[0068] (1) Add lactose and starch to the wet granulator, start stirring and shearing, mix for 5 minutes, add Pemabet, stir and shear and mix for 20 minutes, and clean the powder adhering to the inner wall of the equipment into the mixed material at 5 and 15 minutes respectively;
[0069] (2) Testing the uniformity of the powder content of the material mixture in step (1), the mean content was 97.7% and the RSD was 1.9%;
[0070] (3) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 3 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0071] (4) Drying: sampling about 40 g at the water content of about 5%, 4%, 3%, 2%, 1%, and 0.5% respectively;
[0072] (5) crushing;
[0073] (6) Weigh 25 g of the material from step (5), add low-substituted hydroxypropyl cellulose, lactose, and microcrystalline cellulose, mix in a three-dimensional mixer for 10 min, add magnesium stearate and mix for 5 min;
[0074] (7) Testing the material content in step (6);
[0075] (8) The tablet weight was calculated based on the content results so that each tablet contained 0.1 mg of Pemabet, and the tablets were compressed.
[0076] The results are shown in Tables 3 and 4.
[0077] Table 5 Quality evaluation of different moisture samples of Pemabet granules
[0078]
[0079] The above results show that the moisture content of the dried Pemabet granules affects the dissolution rate of the tablets. When the moisture content is lower than 4%, the dissolution rate at 0:30min can reach more than 85%, and after 3 months of accelerated test, the dissolution rate is not less than 75%; and the lower the moisture value, the higher the dissolution amount. When the moisture value is lower than 2%, there is no significant change in the dissolution rate before and after the accelerated test. Moreover, the moisture content of the dried Pemabet granules also affects the related substances of the tablets. The lower the moisture content, the better the stability of the related substances. Therefore, in the drying process of Pemabet granules, the moisture content needs to be controlled within a range of no more than 4%, preferably no more than 2%, and more preferably no more than 0.5%.
[0080] Test Example 4 Investigation of the proportion of Pemabet particles in the mixed material
[0081] Pemabet granules are a crushed material, and there is a certain difference in fluidity between them and the excipients added subsequently. Their different proportions in the total mixture may affect the tablet weight difference and tablet content uniformity during tableting. Since microcrystalline cellulose excipients have a certain disintegration effect, their ratio with Pemabet granules may affect the dissolution rate of tablets.
[0082] The samples were prepared according to the following recipe process:
[0083] Table 6 Sample prescriptions with different proportions of Pemabet granules
[0084]
[0085]
[0086] Preparation method:
[0087] (1) Add sucrose and mannitol to the wet granulator, start stirring and shearing, mix for 5 minutes, add Pemabet, stir and shear and mix for 20 minutes, and clean the powder adhering to the inner wall of the equipment into the mixed material at 5 and 15 minutes respectively;
[0088] (2) Testing the uniformity of the material mixture in step 1, the content was 98.7%, and the RSD was 2.0%;
[0089] (3) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 3 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0090] (4) Drying, the moisture content is 0.4%;
[0091] (5) crushing, the particle size D90 was 64.3 μm;
[0092] (6) Weigh the materials in step (5) according to the total mixture formula table, add the lactose-microcrystalline cellulose complex, mix in a three-dimensional mixer for 10 minutes, add magnesium stearate and mix for 5 minutes;
[0093] (7) Testing the material content in step (6);
[0094] (8) The tablet weight was calculated based on the content results and the tablets were compressed so that each tablet contained 0.1 mg of Pemabet.
[0095] Table 7 Effect of the proportion of Pemabet granules in the mixed material on tablet quality
[0096]
[0097] The above results show that when the proportion of Pemabet particles in the mixed material does not exceed 10%, the uniformity of the tablet content does not exceed 15%, that is, the smaller the proportion of Pemabet particles in the mixed material, the better the tablet content uniformity and the higher the dissolution rate. Therefore, it is selected that the proportion of Pemabet particles in the mixed material does not exceed 10%, preferably not more than 5%.
[0098] Test Example 5: Investigation of the particle size of Pemabet particles
[0099] The particle size of Pemabet granules can affect the fluidity of tableting materials and tablet dissolution. The samples were prepared according to the following prescription process:
[0100] Table 8 Sample prescriptions of different Pemabet granule sizes
[0101] Pemabet Granules Prescription amount (g) Pemabet 4 lactose 300 starch 100 Purified water Moderate Total mixture Prescription amount (g) Pemabet Granules 40 Microcrystalline Cellulose 156 lactose 200 Magnesium Stearate 4
[0102] Preparation method:
[0103] (1) Add lactose and starch to the wet granulator, start stirring and shearing, mix for 5 minutes, add Pemabet, stir and shear and mix for 20 minutes, and clean the powder adhering to the inner wall of the equipment into the mixed material at 5 and 15 minutes respectively;
[0104] (2) Testing the uniformity of the material mixture in step 1, the content was 97.7%, and the RSD was 2.6%;
[0105] (3) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 3 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0106] (4) Drying, the moisture content is 0.8%;
[0107] (5) Grinding or crushing, the target particle size D90 is about; 200, 150, 100, 50, 25 μm;
[0108] (6) Weigh the materials in step (5) according to the total mixture formula table, add microcrystalline cellulose and lactose, mix in a three-dimensional mixer for 10 minutes, add magnesium stearate and mix for 5 minutes;
[0109] (7) Testing the material content in step (6);
[0110] (8) The tablet weight was calculated based on the content results and the tablets were compressed so that each tablet contained 0.1 mg of Pemabet.
[0111] Table 9 Effect of different pemabet particle sizes on tablet quality
[0112]
[0113] The above results show that when the particle size of the granules containing Pemabet is large after crushing, the total mixture is separated, the uniformity of the tablet content is unqualified, all exceeding 15%, and the dissolution rate of the large particle size sample is low. Therefore, the particle size D90 of Pemabet is selected not to exceed 100 μm, preferably not to exceed 50 μm.
[0114] Example 1
[0115] The samples were prepared according to the following recipe process:
[0116] Pemabet Granules Prescription amount (g) Pemabet 4.0 lactose 136.0 starch 60.0 Purified water Moderate
[0117] Total mixture Prescription amount (g) Pemabet Granules 20.0 Lactose Microcrystalline Cellulose Complex 376.0 Magnesium Stearate 4.0
[0118] Preparation method:
[0119] (1) Add lactose and starch to the wet granulator, start stirring and shearing, mix for 5 minutes, add Pemabet, stir and shear and mix for 20 minutes, and clean the powder adhering to the inner wall of the equipment into the mixed material at 5 and 15 minutes respectively;
[0120] (2) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 3 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0121] (3) Drying;
[0122] (4) crushing;
[0123] (5) Weigh 20.0 g of the material from step (4), add the lactose-microcrystalline cellulose complex, mix in a three-dimensional mixer for 10 min, add magnesium stearate and mix for 5 min;
[0124] (6) Testing the material content in step (5);
[0125] (7) Calculate the theoretical tablet weight based on the content results and press the tablets.
[0126] Table 10 Test data of Example 1
[0127]
[0128]
[0129] Example 2
[0130] The samples were prepared according to the following recipe process:
[0131] Pemabet Granules Prescription amount (g) Pemabet 4.0 lactose 136.0 starch 60.0 Purified water Moderate
[0132] Total mixture Prescription amount (g) Pemabet Granules 20.0 Lactose Microcrystalline Cellulose Complex 376.0 Magnesium Stearate 4.0
[0133] Preparation method:
[0134] (1) Add lactose and starch to the wet granulator, start stirring and shearing, mix for 5 minutes, add Pemabet, stir and shear and mix for 20 minutes, and clean the powder adhering to the inner wall of the equipment into the mixed material at 5 and 15 minutes respectively;
[0135] (2) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 3 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0136] (3) Drying;
[0137] (4) crushing;
[0138] (5) Weigh 20.0 g of the material from step (4), add the lactose-microcrystalline cellulose complex, mix in a three-dimensional mixer for 10 min, add magnesium stearate and mix for 5 min;
[0139] (6) Testing the material content in step (5);
[0140] (7) Calculate the theoretical tablet weight based on the content results and press the tablets.
[0141] Table 11 Test data of Example 2
[0142]
[0143]
[0144] Example 3
[0145] The samples were prepared according to the following recipe process:
[0146] Pemabet Granules Prescription amount (g) Pemabet 20.0 Mannitol 200.0 Purified water Moderate
[0147] Total mixture Prescription amount (g) Pemabet Granules 4.4 lactose 111.6 Microcrystalline Cellulose 268.0 Hydroxypropyl methylcellulose 12.0 Magnesium Stearate 4.0
[0148] Preparation method:
[0149] (1) Pemabet and mannitol were added to the wet granulator and stirred and sheared for 20 minutes. The powder adhering to the inner wall of the equipment was cleaned and mixed into the mixed material at 5 and 15 minutes respectively;
[0150] (2) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 2 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0151] (3) Drying;
[0152] (4) crushing;
[0153] (5) Weigh 4.4 g of the material from step (4), add lactose, microcrystalline cellulose, and hypromellose, place in a three-dimensional mixer and mix for 10 min, add magnesium stearate and mix for 5 min;
[0154] (6) Testing the material content in step (5);
[0155] (7) Calculate the theoretical tablet weight based on the content results and press the tablets.
[0156] Table 12 Test data of Example 3
[0157]
[0158]
[0159] Example 4
[0160] The samples were prepared according to the following recipe process:
[0161] Pemabet Granules Prescription amount (g) Pemabet 2.0 starch 200.0 Purified water Moderate
[0162] Total mixture Prescription amount (g) Pemabet Granules 40.4 Mannitol 323.6 Croscarmellose Sodium 12.0 Hydroxypropyl Cellulose 20.0 Magnesium Stearate 4.0
[0163] Preparation method:
[0164] (1) Pemabet and starch were added into the wet granulator and stirred and sheared for 20 min. The powder adhering to the inner wall of the equipment was cleaned and mixed into the mixed material at 5 and 15 min respectively;
[0165] (2) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 3 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0166] (3) Drying;
[0167] (4) crushing;
[0168] (5) Weigh 40.4 g of the material from step (4), add mannitol, cross-linked sodium carboxymethyl cellulose, and hydroxypropyl cellulose, mix in a three-dimensional mixer for 10 min, add magnesium stearate and mix for 5 min;
[0169] (6) Testing the material content in step (5);
[0170] (7) Calculate the theoretical tablet weight based on the content results and press the tablets.
[0171] Table 13 Test data of Example 4
[0172]
[0173]
[0174] Example 5
[0175] The samples were prepared according to the following recipe process:
[0176] Pemabet Granules Prescription amount (g) Pemabet 10.0 sucrose 100.0 starch 140.0 Purified water Moderate
[0177] Total mixture Prescription amount (g) Pemabet Granules 10.0 Lactose Microcrystalline Cellulose Starch Complex 386.0 talcum powder 4.0
[0178] Preparation method:
[0179] (1) Add sucrose and starch into a wet granulator and stir and mix for 5 minutes. Add Pemabet and stir and shear mix for 20 minutes. Clean the powder adhering to the inner wall of the equipment and add it into the mixed material at 5 and 15 minutes respectively.
[0180] (2) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 2 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0181] (3) Drying;
[0182] (4) crushing;
[0183] (5) Weigh 10.0 g of the material from step (4), add lactose-microcrystalline cellulose-starch complex, mix in a three-dimensional mixer for 10 min, add talcum powder and mix for 5 min;
[0184] (6) Testing the material content in step (5);
[0185] (7) Calculate the theoretical tablet weight based on the content results and press the tablets.
[0186] Table 14 Example 5 test data
[0187]
[0188]
[0189] Example 6
[0190] The samples were prepared according to the following recipe process:
[0191] Pemabet Granules Prescription amount (g) Pemabet 2.0 starch 100.0 Lactose Monohydrate 98.0 Purified water Moderate
[0192] Total mixture Prescription amount (g) Pemabet Granules 40.0 Calcium Hydrogen Phosphate 80.0 Mannitol 216.0 Pregelatinized starch 60.0 Magnesium Stearate 4.0
[0193] Preparation method:
[0194] (1) Starch and lactose monohydrate were added to the wet granulator and stirred for 5 minutes. Pemabet was added and stirred for 20 minutes. The powder adhering to the inner wall of the equipment was cleaned and added to the mixed material at 5 and 15 minutes respectively.
[0195] (2) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 3 minutes. After adding water, continue stirring and shearing for 1 minute;
[0196] (3) Drying;
[0197] (4) crushing;
[0198] (5) Weigh 40.0 g of the material from step (4), add calcium hydrogen phosphate, mannitol, and pregelatinized starch, place in a three-dimensional mixer and mix for 10 min, add magnesium stearate and mix for 5 min;
[0199] (6) Testing the material content in step (5);
[0200] (7) Calculate the theoretical tablet weight based on the content results and press the tablets.
[0201] Table 15 Example 6 Test Data
[0202]
[0203]
[0204] Test Example 6: Stability Study
[0205] The samples of Examples 1-6 were packaged in aluminum-plastic blisters and kept at 40°C / 75%RH. The content, related substances and solubility were tested after 3 months.
[0206] Table 16 Stability data of samples of Examples 1-6
[0207] Test items Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 content(%) 97.7 100.2 100.1 99.1 98.9 98.7 Related substances (%) 1.54 0.46 1.06 1.12 0.62 1.33 Dissolution (%) 88.0 94.3 92.5 82.7 95.6 80.8
[0208] The above results show that under the preparation process defined in the present invention: after the prepared Pemabet tablets were stored at 40°C / 75% RH for 3 months, the content, related substances and solubility all met the standards. The Pemabet tablets prepared by the present invention by combining the wet granulation process with the powder direct tableting process have a low initial impurity level and good physical and chemical stability. After long-term storage, they can ensure definite efficacy and safety. Compared with conventional production methods, the present invention does not require special and more production process controls, can effectively reduce the adverse effects of slight deviations in process parameters on product quality, and saves energy and reduces production costs.
[0209] Comparative Example 1
[0210] Pemabet tablets were prepared using a separate wet granulation process, and samples were prepared according to the following prescription process to investigate the changes in related substances at time 0 and during the stability period.
[0211] Raw materials Prescription amount (g) Pemabet 1 lactose 439 Microcrystalline Cellulose 450 Croscarmellose Sodium 50 Hydroxypropyl Cellulose 50 Magnesium Stearate Appropriate amount, accounting for 1% of the weight of the particles after drying Purified water Moderate
[0212] Preparation process:
[0213] (1) Add lactose, microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, and hydroxypropyl cellulose to a wet granulator, start stirring and shearing, and add Pemabet after mixing for 5 minutes. Stir and shear mix for 20 minutes, and clean the powder adhering to the inner wall of the equipment into the mixed material at 5, 15, and min, respectively;
[0214] (2) Testing the uniformity of material mixing in step (1), the RSD was 4.7%;
[0215] (3) Continue stirring and shear mixing for 30 min; test the mixing uniformity, the RSD is 2.1%;
[0216] (5) Add water to make a soft material while maintaining stirring and shearing. Use a spray gun to add purified water for 2 minutes. After adding water, continue stirring and shearing for 2 minutes;
[0217] (6) Use a rocking granulator with a 16-mesh screen;
[0218] (7) Drying, the moisture content is 3.8%;
[0219] (8) Manually granulate the pellets using a 16-mesh sieve, add 1% by weight of magnesium stearate, and mix for 5 minutes;
[0220] (9) Testing the content of the material in step (8);
[0221] (10) Calculate the theoretical tablet weight based on the content results and press the tablets.
[0222] Table 17 Comparative Example 1 Test Data
[0223] Test items Comparative Example 1-0 Comparative Example 1 - 40°C 75% RH 3 months Sheet hardness (N) 74.2 / Tablet weight difference RSD (%) 1.9 / Content uniformity A+2.2S (%) 9.2 / Related substances (%) 0.29 2.83 Dissolution (%) 95.2 93.8
[0224] The results in the above table show that for the Pemabet tablets prepared by a single wet granulation process, the RSD of the powder mixing content uniformity exceeded 3.0% at 20 minutes. Due to the low proportion of API, the mixing time must be extended to ensure that the powder content uniformity is qualified. Moreover, since the active ingredients are in contact with cellulose excipients, the related substances also increased significantly after the samples were retained at 40°C and 75% RH for 3 months, and the chemical stability was poor.
[0225] Comparative Example 2
[0226] Pemabet tablets were prepared using a separate powder direct tableting process. Samples were prepared according to the following prescription process to investigate the changes in related substances at time 0 and during the stability period.
[0227]
[0228]
[0229] Preparation process:
[0230] (1) Add Pemabet and 10 g lactose into a three-dimensional mixer and mix for 5 min;
[0231] (2) Add 100 g lactose and mix for 5 min;
[0232] (3) Add the remaining lactose and mix for 5 minutes;
[0233] (4) Add microcrystalline cellulose and mix for 5 minutes;
[0234] (5) Testing the uniformity of material mixing in step (4), the RSD was 10.4%;
[0235] (6) Continue mixing for 30 min and test the mixing uniformity. The RSD is 3.4%.
[0236] (7) Continue mixing for 1 h and test the mixing uniformity. The RSD is 2.8%;
[0237] (8) Add magnesium stearate and mix for 5 minutes;
[0238] (9) testing the sample content in step (8);
[0239] (10) Tableting.
[0240] Table 18 Comparative Example 2 Test Data
[0241] Test items Comparative Example 2-0 Comparative Example 2 - 40°C 75% RH 3 months Sheet hardness (N) 66.9 / Tablet weight difference RSD (%) 0.8 / Content uniformity A+2.2S (%) 3.6 / Related substances (%) 0.11 2.26 Dissolution (%) 100.2 98.1
[0242] The results in the table above show that the single powder direct tableting process makes it more difficult to mix the lower dose of Pemabet uniformly, and a long period of mixing is required to make the powder content uniform. In addition, after the prepared Pemabet tablets were kept at 40℃75%RH for 3 months, the related substances increased significantly, and the chemical stability was poor.
Claims
1. A method for preparing Pemabet tablets, It is characterized in that The following steps are involved: (1) preparing granules containing Pemabet and non-cellulose excipients, drying, and detecting the moisture content of the granules; (2) crushing the granules containing Pemabet and mixing them with direct compression tablet excipients; (3) adding lubricant and tableting; The non-cellulose auxiliary material includes one or a combination of any two or more of sucrose, starch, lactose, lactose hydrate, and mannitol; The direct compression tablet excipients include one or a combination of any two or more of lactose, sucrose, microcrystalline cellulose, mannitol, phosphate, lactose-microcrystalline cellulose complex, and lactose-microcrystalline cellulose-starch complex.
2. The preparation method according to claim 1, It is characterized in that The direct compression tablet excipient is preferably a lactose-microcrystalline cellulose complex or a lactose-microcrystalline cellulose-corn starch complex.
3. The preparation method according to claim 1, It is characterized in that In the composition of Pemabet and non-cellulose auxiliary materials in step (1), the ratio of Pemabet to auxiliary materials is 1:10 to 1:100, preferably 1:10 to 1:
50.
4. The preparation method according to claim 1, It is characterized in that The moisture content of the material after drying in step (1) does not exceed 4.0%, preferably does not exceed 2.0%, and more preferably does not exceed 0.5%.
5. The preparation method according to claim 1, It is characterized in that The particle size D90 of the particles containing Pemabet after crushing in step (2) does not exceed 100 μm, preferably does not exceed 50 μm.
6. The preparation method according to claim 1, It is characterized in that In step (2), the proportion of Pemabet particles in the mixed material does not exceed 10% (w / w), preferably does not exceed 5% (w / w).
7. The preparation method according to claim 1, It is characterized in that Lubricants, disintegrants and binders may be added in the preparation step (2).
8. The preparation method according to claim 7, It is characterized in that The lubricant is magnesium stearate or talc.
9. The preparation method according to claim 7, It is characterized in that The disintegrant is one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and cross-linked sodium carboxymethyl cellulose.
10. The preparation method according to claim 7, It is characterized in that The adhesive is one or more of pregelatinized starch, copovidone, hydroxypropyl methylcellulose, ethyl cellulose, and hydroxypropyl cellulose.
Citation Information
Patent Citations
Pharmaceutical preparation
CN110809470A
